Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Change in Intangibles (2020)

AbCellera Biologics' Change in Intangibles history spans 1 years, with the latest figure at $5.0 million for Q1 2020.

For the quarter ending Q1 2020, Change in Intangibles changed N/A year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Dec 2020, changed N/A, and an annual FY2023 reading of $560000.0, down 72.0% over the prior year.
Change in Intangibles for Q1 2020 was $5.0 million at AbCellera Biologics.
The five-year high for Change in Intangibles was $5.0 million in Q1 2020, with the low at $5.0 million in Q1 2020.